Quick Takeaways
- Schonfeld Strategic Advisors LLC filed SCHEDULE 13G/A for Fate Therapeutics, Inc. Common Stock, par value $0.001 per share (FATE).
- Disclosed ownership: 0.82%.
- Date of event: 30 Jun 2025.
Schonfeld Strategic Advisors LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Fate Therapeutics, Inc. Common Stock, par value $0.001 per share (FATE)
- Filing Manager
- Schonfeld Strategic Advisors LLC
- Reporting Manager
- Schonfeld Strategic Advisors LLC
- Symbol
- FATE
- Shares outstanding
- 114,331,829 shares
- Disclosed Ownership
- 937,521 shares
- Ownership
- 0.82%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 16:30:12 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Schonfeld Strategic Advisors LLC disclosed 0.82% ownership in Fate Therapeutics, Inc. Common Stock, par value $0.001 per share (FATE) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Aug 2025, 16:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Schonfeld Strategic Advisors LLC | 0.82% | 937,521 | 937,521 | 0 | /s/ Hung Luc | Hung Luc, Chief Compliance Officer |